Search results
Results from the WOW.Com Content Network
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, India. It was founded by Kiran Mazumdar-Shaw in 1978. [ 4 ] The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, [ 5 ] including the United States and Europe. [ 4 ]
Indian drugmaker Biocon, looking to grab a piece of the exploding weight-loss drug market as early as possible, is developing its own version of Novo Nordisk's wildly popular Wegovy and is ...
Kiran Mazumdar-Shaw (born 23 March 1953) is an Indian billionaire entrepreneur. [3] She is the executive chairperson and founder of Biocon Limited and Biocon Biologics Limited, [4] a biotechnology company based in Bangalore, India [5] and the former chairperson of Indian Institute of Management, Bangalore. [6]
Divi's Laboratories Limited is an Indian multinational pharmaceutical company and producer of active pharmaceutical ingredients (APIs) and intermediates, headquartered in Hyderabad. [ 5 ] [ 6 ] [ 2 ] [ 7 ] The company manufactures and custom synthesizes generic APIs, intermediates.
Indian drugmaker Biocon Ltd is in talks with generic drugmaker Mylan for a merger of their biosimilar businesses, financial news website Moneycontrol reported on Thursday, citing sources with ...
India-based Biocon Ltd is reportedly in talks with generic drugmaker Mylan for a merger of their biosimilar businesses, financial news website Moneycontrol reported, citing sources with direct ...
Divisional applications are generally used in cases where the parent application may lack unity of invention; that is, the parent application describes more than one invention and the applicant is required to split the parent into one or more divisional applications each claiming only a single invention.
The main effect of stock splits is an increase in the liquidity of a stock: [3] there are more buyers and sellers for 10 shares at $10 than 1 share at $100. Some companies avoid a stock split to obtain the opposite strategy: by refusing to split the stock and keeping the price high, they reduce trading volume.